Does resveratrol slow aging?
Short answer
Not shown in people.
Resveratrol lengthened life mainly in yeast and worms. In older people, small trials of memory and physical function disagree, and a pooled review of six studies found no effect on memory.
This page says what the research shows. It does not say whether you should take resveratrol.
Where the evidence stands
Each dot is one on-topic paper. Steps near the top answer the question more directly. Select a dot to see the study.
↑ Stronger evidence
-
Trials in people: aging and age-related decline
Trials that measured aging and age-related disease directly.
3 -
Trials in people: other measures
Trials that measured other health or performance measures.
3 -
Trials in people: lab tests or safety
Trials that measured lab tests, side effects or safety.
7 -
Population studies
Studies that followed or surveyed groups of people. They show links, not causes.
1 -
Blood levels and genes
Studies that link blood levels or genes to health.
1 -
Animals
Studies in mice, rats, worms or flies.
1
↓ Weaker evidence
- Points to benefit
- Mixed
- No difference
- No direction
- Points to harm
Not on the ladder: 4 reviews of many studies (shown below), 2 opinion or narrative papers. Counts are papers, not people. Some studies appear in more than one paper.
See every studyWhat we found
- A 2012 pooled analysis of 19 papers in six species found resveratrol lengthened life most in yeast and worms, with less reliable effects in higher animals. Hector 2012
- A pooled review of six studies in older adults found no clear effect of resveratrol on delayed, immediate or working memory, or on processing speed. Sánchez-Nieto 2023
- In 125 postmenopausal women taking resveratrol for 12 months versus placebo, overall thinking scores were 33% better, a small effect (Cohen's d = 0.170). Thaung Zaw 2021
- Among 783 adults aged 65 or older followed for 9 years, resveratrol levels from diet were not linked to risk of death. Semba 2014
What the research says
Memory and thinking: mixed results in older adults
In the longest trial, 125 postmenopausal women scored 33% better overall on thinking tests with resveratrol than placebo after 12 months. Over 26 weeks, 60 adults aged 60 to 79 showed no verbal memory change. A 90-day pilot in 32 people improved one speed test at 1000 mg/day.
Pooled across six studies, resveratrol showed no clear effect on any memory measure or on processing speed. A survey of older Mediterranean adults linked higher resveratrol intake to lower odds of thinking problems, but such a study shows a link, not a cause.
Studies: Thaung Zaw 2021, Huhn 2018, Anton 2018, Sánchez-Nieto 2023, Micek 2023
Physical function: one trial helped, one blunted exercise
In 129 people with knee osteoarthritis, the resveratrol group improved balance, walking speed, knee bending and grip strength over 18 weeks (all p < 0.05, meaning unlikely to be chance). Knee score and pain at rest did not change.
Two exercise trials point different ways. In inactive men aged about 65, resveratrol cut the fitness gain from training: oxygen uptake rose 45% more on placebo. In a 60-person pilot, walking distance rose 33.1 meters on 1000 mg/day and 9.45 meters on placebo, with no between-group test reported.
Studies: Karim 2026, Gliemann 2013, Harper 2021
Stand-in markers moved, but not always for the better
Several trials found changes in stand-in measures. In postmenopausal women, 12 months raised spine bone density (+0.016 g/cm2). In 30 older adults with poor blood sugar control, a blood vessel test improved but blood sugar did not. In older adults with diabetes, 1000 mg/day raised antioxidant capacity.
These are markers, not aging itself. Some went the other way: a heart-risk marker, TMAO, rose in all groups regardless of resveratrol, and in a trial of 26 weeks some inflammation markers rose in both groups, partly more with resveratrol.
Studies: Wong 2020, Pollack 2017, García-Martínez 2023, Wong 2016, Gonçalinho 2023, Baptista 2024, Huhn 2018
Longer life: shown only in animals and yeast
Across 19 papers in six species, resveratrol lengthened life overall, most in yeast and worms, and less reliably in most higher animals. The authors questioned selling it as a life-extending supplement for humans. In middle-aged mice on a high-calorie diet, it raised survival.
In 19 rodent studies of Alzheimer's disease, resveratrol protected nerves, but study quality was low and risk of bias high. No study here measured lifespan in people.
Studies: Hector 2012, Baur 2006, Chen 2019
Diet levels and death: no link found
In 783 adults aged 65 or older in Italy, the share who died over 9 years was 34.4% in the lowest and 37.4% in the highest urine-resveratrol group (P = .67, meaning the gap could easily be chance).
Levels were also not linked to inflammation, heart disease or cancer. This study measured resveratrol from ordinary diet, not supplements, and shows links, not causes.
Studies: Semba 2014
What reviews of many studies found
Reviews pool or sum up earlier studies. They are not on the ladder, because they repeat studies already counted there.
Pooled review (meta-analysis) · Sánchez-Nieto 2023
Pooled six studies in older adults. Found no clear effect on delayed, immediate or working memory, or processing speed (processing speed SMD = 0.25, p = 0.55, meaning no clear difference). Authors call for studies of other doses and lengths.
Pooled review (meta-analysis) · Hector 2012
Pooled survival data from 19 papers in six species, from yeast to mice. Resveratrol lengthened life overall, most in yeast and worms; few species showed it clearly. Authors questioned marketing it as a life-extending supplement for humans.
Systematic review · Chen 2019
Pooled 19 studies in rodents bred to get Alzheimer's disease. Found steady nerve-protecting effects, but study quality was low, no study calculated sample size, and risk of bias was high.
Systematic review · Shuid 2025
Reviewed 28 bone studies: 14 cell, 8 cell-plus-animal, 6 animal and 1 survey of postmenopausal women. Resveratrol helped bone-building pathways in lab work; poor absorption is a problem and human studies are needed.
How the research grew
The papers we read span 2006 to 2026. 4 of the 22 on-topic papers came out in 2024 to 2026. The earliest trial in people here is from 2013.
- 2005–09
- 2010–14
- 2015–19
- 2020–24
- 2025–26
Each dot is one on-topic paper, colored by what it found. Rings mark key papers:
- 2006. Mice on rich diet lived longer with resveratrol. Baur 2006
- 2012. Cross-species pooling: longer life mostly in simple organisms. Hector 2012
- 2014. Diet resveratrol levels not linked to death. Semba 2014
- 2021. Longest human trial, 24-month crossover: small thinking gain. Thaung Zaw 2021
- 2023. Pooled memory studies in older adults: no effect. Sánchez-Nieto 2023
Doses tested
11 trial papers gave a set daily amount in mg a day, from 150 to 3,000. Each dot shows the dose and what the trial found.
- mg a day, log scale1001,00010,000
- Points to benefit
- Mixed
- No difference
- No direction
- Points to harm
One row per paper, so a trial reported in two papers appears twice.
Not shown: 2 trial papers with no single daily dose in the abstract, or a different unit.
Who funds this research
Two of 13 trial papers have a company stake: an author consulted for Reserveage Organics, the pill supplier. Six lack a PubMed disclosure. The 2006 mouse study declared competing interests. Confidence was not lowered: several positive trials declared none.
- Company stake 2
- No disclosure in PubMed 6
- No stake declared 5
- Anton 2018Company stake
- Harper 2021Company stake
- Wong 2020No disclosure in PubMed
- Diaz 2020No disclosure in PubMed
- Wong 2016No disclosure in PubMed
- Gliemann 2013No disclosure in PubMed
- Pollack 2017No disclosure in PubMed
- Huhn 2018No disclosure in PubMed
- Thaung Zaw 2021No stake declared
- García-Martínez 2023No stake declared
- Gonçalinho 2023No stake declared
- Baptista 2024No stake declared
- Karim 2026No stake declared
Funding rule. A stake is always shown. Confidence is lowered only when every supporting study comes from a party with a stake. "No disclosure in PubMed" means the PubMed record has no conflict-of-interest statement. It does not mean there is no conflict.
All 22 on-topic papers
Each paper shows what it tested, what it found, and who has a stake. Every paper also has its own page that explains how much it counts and how it fits. See every study as a list.
-
Randomized trial · measured the question itselfThaung Zaw et al., 2021Clinical nutrition (Edinburgh, Scotland) · PubMed
Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study.
125 people · Postmenopausal women aged 45 to 85
TestedResveratrol 75 mg twice daily vs placebo, each for 12 months, then switched (24-month crossover)
Overall thinking performance was 33% better than placebo (Cohen's d = 0.170, P = 0.005). Brain blood flow, fasting insulin and insulin resistance also improved.
Points to benefitNo stake declaredAbstract onlyNo conflict of interest declared.
-
Randomized trial · measured the question itselfAnton et al., 2018Journal of alternative and complementary medicine (New York, N.Y.) · PubMed
Effects of 90 Days of Resveratrol Supplementation on Cognitive Function in Elders: A Pilot Study.
32 people · Overweight, inactive adults aged 65 to 93
TestedResveratrol 300 mg a day or 1000 mg a day vs placebo for 90 days
Speed on one test, Trail Making part A, improved on 1000 mg/day vs 300 mg and placebo (p = 0.02). Other thinking skills did not change significantly.
MixedCompany stakeAbstract onlyDr. Anton was a scientific advisor and consultant for Reserveage Organics, which made the resveratrol used.
-
Effects of resveratrol on memory performance, hippocampus connectivity and microstructure in older adults - A randomized controlled trial.
60 people · Healthy adults aged 60 to 79
TestedResveratrol 200 mg a day vs placebo for 26 weeks
No clear change in verbal memory (main test). Pattern memory showed a trend to hold up on resveratrol (n.s., p = 0.07). Several blood markers, including inflammation, rose in both groups, partly more with resveratrol.
No differenceNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Improvement in postural imbalance with intake of resveratrol (polyphenolic phytoalexin) in patients of knee osteoarthritis.
129 people · Adults with knee osteoarthritis (a joint problem common in older age)
TestedResveratrol 500 mg a day vs placebo for 18 weeks
Balance, gait speed, knee range of motion and handgrip strength improved, and walking pain and WOMAC scores fell (all p < 0.05). Oxford Knee Score and resting pain did not change.
Points to benefitNo stake declaredAbstract onlyNo competing interests declared.
-
Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial.
60 people · Community-living adults, average age 71.8, with trouble walking or moving
Tested12 weeks of exercise plus placebo, or plus resveratrol 500 mg a day, or plus 1000 mg a day
Side effects were similar across groups. Six-minute walk gain was 9.45 m with placebo, 22.9 m on 500 mg and 33.1 m on 1000 mg. Gait speed changed little (-0.04 to 0.04 m/s).
MixedCompany stakeAbstract onlyOne author is a consultant for Reserveage Organics, which supplied the resveratrol and placebo pills.
-
Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men.
27 people · Healthy, inactive men around 65 years old
TestedResveratrol 250 mg a day vs placebo for 8 weeks, while doing high-intensity exercise training
Exercise raised maximal oxygen uptake 45% more in the placebo group than the resveratrol group (P < 0.05). Blood pressure fell only on placebo (-4.8 ± 1.7 mmHg). Resveratrol also blocked the exercise gains in cholesterol and triglycerides.
Points to harmNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Effects of resveratrol on changes in trimethylamine-N-oxide and circulating cardiovascular factors following exercise training among older adults.
41 people · Older adults (average age 72.1) at high risk of heart disease
TestedResveratrol 500 or 1000 mg a day vs placebo, plus 12 weeks of group exercise
A gut-made heart risk marker (TMAO) rose over time in all groups, regardless of treatment (p = 0.04). Resveratrol changed other blood chemicals in a dose-dependent way, but not TMAO.
No differenceNo stake declaredAbstract onlyNo competing interests declared.
-
Randomized trial · lab tests or safetyGarcía-Martínez et al., 2023International journal of molecular sciences · PubMed
Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes.
97 people · Older adults with type 2 diabetes
TestedResveratrol 1000 mg a day or 500 mg a day vs placebo for 6 months
On 1000 mg/day, total antioxidant capacity and sirtuin 1 levels rose (p < 0.05). In the placebo group, lipoperoxides, isoprostanes and C-reactive protein rose (p < 0.05).
Points to benefitNo stake declaredAbstract onlyNo competing interests declared.
-
Sirtuin 1 and Vascular Function in Healthy Women and Men: A Randomized Clinical Trial Comparing the Effects of Energy Restriction and Resveratrol.
48 people · Healthy adults aged 55 to 65
TestedResveratrol supplements or eating fewer calories, for 30 days; no placebo group
Both resveratrol and calorie cutting raised circulating SIRT1 (p < 0.001) and lowered noradrenaline (resveratrol: p = 0.037). Vessel widening tests are reported only as links to SIRT1.
Points to benefitNo stake declaredAbstract onlyNo competing interests declared.
-
Randomized trial · lab tests or safetyWong et al., 2020Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · PubMed
Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial.
Postmenopausal women without bone disease
TestedResveratrol 75 mg twice daily vs placebo, each for 12 months, then switched (24-month crossover)
After 12 months, bone density rose in the lumbar spine (+0.016 ± 0.003 g/cm2) and femoral neck (+0.005 ± 0.002 g/cm2). A bone breakdown marker fell 7.24% vs placebo.
Points to benefitNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Trial, not randomized · lab tests or safetyDiaz et al., 2020Scandinavian cardiovascular journal : SCJ · PubMed
Acute resveratrol supplementation in coronary artery disease: towards patient stratification.
10 people · Older adults (average age 66.6) with heart artery disease
TestedResveratrol 330 mg three times a day for 3 days plus one more dose on day 4, vs placebo, in a crossover
Blood vessel widening (FMD) improved after bypass surgery (-1.4 vs. 5.0%; p = .004) but not after stent procedures (4.2 vs. -0.2%; NS). Authors say it impaired FMD in the stent group.
MixedNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Randomized trial · lab tests or safetyPollack et al., 2017The journals of gerontology. Series A, Biological sciences and medical sciences · PubMed
Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults.
30 people · Older adults with poor blood sugar control
TestedResveratrol 2 to 3 g a day vs placebo, 6 weeks each, in a crossover
No change in glucose tolerance, insulin sensitivity, weight, blood pressure or blood fats. Blood vessel test improved (2.02 ± 0.2 vs 1.76 ± 0.02, p = .002). Muscle mitochondria number rose.
MixedNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Randomized trial · lab tests or safetyWong et al., 2016Nutrition, metabolism, and cardiovascular diseases : NMCD · PubMed
Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus.
36 people · Older adults with type 2 diabetes and no dementia, aged 49 to 78
TestedSingle doses of resveratrol 0, 75, 150 and 300 mg, one week apart, in a crossover
Brain blood vessel response to carbon dioxide rose vs placebo: 13.8 ± 3.5% for 75 mg (P = 0.001), 8.9 ± 3.5% for 150 mg, 13.7 ± 3.3% for 300 mg.
Points to benefitNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Population study: one-time surveyMicek et al., 2023International journal of food sciences and nutrition · PubMed
Association between alcoholic (poly)phenol-rich beverage consumption and cognitive status in older adults living in a Mediterranean area.
Older adults in a Mediterranean area
TestedCompared people by how much red wine, white wine, beer and dietary resveratrol they consumed
Higher resveratrol intake went with lower odds of cognitive impairment. Middle and top red wine tertiles had lower odds. Top white wine tertile also did. Beer showed no link.
Points to benefitNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Resveratrol levels and all-cause mortality in older community-dwelling adults.
783 people · Men and women aged 65 or older in two Italian villages, followed for 9 years
TestedCompared people with the lowest to highest urine levels of resveratrol from diet
268 (34.3%) died. Lowest-level group had a hazards ratio for death of 0.80 (95% CI, 0.54-1.17) vs highest. No link to inflammation markers, heart disease or cancer.
No differenceNo stake declaredAbstract onlyNo conflicts declared; funded by US government health institutes.
-
Resveratrol improves health and survival of mice on a high-calorie diet.
Middle-aged mice fed a high-calorie diet
TestedResveratrol vs no resveratrol in mice on a high-calorie diet
Resveratrol raised survival of middle-aged mice on a high-calorie diet. It improved insulin sensitivity, motor function and mitochondrial number, lowered IGF-I, and opposed the diet's effects in 144 out of 153 altered pathways.
Points to benefitCompany stakeAbstract onlyAuthors declare competing financial interests; details are on the Nature website, not in PubMed.
-
A Systematic Review on the Molecular Mechanisms of Resveratrol in Protecting Against Osteoporosis.
28 studies · Mostly cells and animals; one study in postmenopausal women
TestedResveratrol and bone-cell pathways: 14 cell studies, 8 mixed, 6 animal, 1 cross-sectional
Of 513 articles found, 28 were included. Authors say resveratrol helped bone-building cells and blocked bone breakdown in lab and animal work. Low absorption is a problem; human studies are needed.
Points to benefitNo stake declaredAbstract onlyNo conflicts declared; no sponsor funding.
-
[Effect of resveratrol on cognitive functions in older adults: a systematic review and meta-analysis].
6 studies · Older adults
TestedResveratrol vs comparison on memory and thinking speed, pooled from 6 studies
No clear effect on delayed memory (SMD = 0.69, 95 % CI: 0.85-2.23, p = 0.38), immediate memory (SMD = 0.56, p = 0.15), working memory (SMD = -0.21, p = 0.43) or processing speed (SMD = 0.25, p = 0.55).
No differenceNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies.
19 studies · Rodents bred to have Alzheimer's disease
TestedResveratrol vs no treatment in 19 rodent studies
Authors report steady nerve-protecting effects in Alzheimer's models. They note low study quality, no sample size calculations and high risk of bias.
Points to benefitNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
The effect of resveratrol on longevity across species: a meta-analysis.
19 studies · Yeast, worms, mice, fruit flies and killifish
TestedResveratrol vs no resveratrol on lifespan, pooled from 19 papers
Overall, resveratrol extended life. The effect was strongest in yeast and worms and less reliable in higher species. Few species showed clear life extension. Authors question selling it as a life-extending supplement.
MixedNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
SIRT1, resveratrol and aging.
Not applicable; review of aging research in yeast, worms, flies, mice and humans
TestedThe SIRT1 protein and resveratrol and their link to aging
Reviews why SIRT1 and resveratrol were studied as ways to extend health and lifespan, from animals to human studies. It gives no numbers.
No weight on the ladderNo stake declaredAbstract onlyNo competing interests declared.
-
Prospective Pharmacological Potential of Resveratrol in Delaying Kidney Aging.
Not applicable; review of kidney aging research
TestedResveratrol and the aging kidney
Reviews how resveratrol may slow kidney aging through pathways such as sirtuin 1, AMPK and NF-κB. It is not a pooled analysis and gives no numbers.
No weight on the ladderNo stake declaredAbstract onlyNo competing interests declared.
26 papers we read and set aside as off topic
- Chan et al., 2024. Cosmeceuticals in photoaging: A review. (systematic review)
- Farinetti et al., 2017. Mediterranean diet and colorectal cancer: A systematic review. (systematic review)
- Hecker et al., 2022. The impact of resveratrol on skin wound healing, scarring, and aging. (systematic review)
- Wei et al., 2024. Resveratrol's bibliometric and visual analysis from 2014 to 2023. (other)
- Lemos et al., 2026. Resveratrol supplementation and assisted reproduction outcomes: A systematic review and meta-analysis. (pooled review (meta-analysis))
- Lan et al., 2022. Effects of resveratrol on renal ischemia-reperfusion injury: A systematic review and meta-analysis. (pooled review (meta-analysis))
- Ahmadi et al., 2025. Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients. (randomized trial)
- Zemel, 2020. Modulation of Energy Sensing by Leucine Synergy with Natural Sirtuin Activators: Effects on Health Span. (randomized trial)
- Gualdoni et al., 2014. Resveratrol enhances TNF-α production in human monocytes upon bacterial stimulation. (trial, not randomized)
- Farzin et al., 2020. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. (randomized trial)
- Biswas et al., 2020. Antioxidant Activity with Increased Endogenous Levels of Vitamin C, E and A Following Dietary Supplementation with a Combination of Glutathione and Resveratrol Precursors. (randomized trial)
- Qiang et al., 2018. Resveratrol improves efficacy of oral amoxicillin against childhood fast breathing pneumonia in a randomized placebo-controlled double blind clinical trial. (randomized trial)
- Scotto di Palumbo et al., 2022. Effects of a Long Chain n-3 Polyunsaturated Fatty Acid-rich Multi-ingredient Nutrition Supplement on Body Composition and Physical Function in Older Adults with Low Skeletal Muscle Mass. (randomized trial)
- Vors et al., 2018. Supplementation with Resveratrol and Curcumin Does Not Affect the Inflammatory Response to a High-Fat Meal in Older Adults with Abdominal Obesity: A Randomized, Placebo-Controlled Crossover Trial. (randomized trial)
- Opie et al., 2007. The red wine hypothesis: from concepts to protective signalling molecules. (opinion or narrative review)
- Zhou et al., 2024. Resveratrol triggers autophagy-related apoptosis to inhibit the progression of colorectal cancer via inhibition of FOXQ1. (cell study)
- Li et al., 2023. Alcohol and the vasculature: a love-hate relationship? (opinion or narrative review)
- Penumathsa et al., 2009. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. (opinion or narrative review)
- Ochiai et al., 2019. Influence of resveratrol supplementation on IVF-embryo transfer cycle outcomes. (population study: one-time survey)
- Jaskulski et al., 2020. Prognostic associations of circulating phytoestrogens and biomarker changes in long-term survivors of postmenopausal breast cancer. (blood level study)
- Rabbani et al., 2022. Emerging Glycation-Based Therapeutics-Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors. (opinion or narrative review)
- de Oliveira et al., 2023. Polymeric Nanoparticles for the Treatment of Prostate Cancer- Technological Prospecting and Critical Analysis. (other)
- Prud'homme et al., 2022. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. (opinion or narrative review)
- Cai et al., 2023. Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosis. (animal study)
- Huang et al., 2024. Copper overload exacerbates testicular aging mediated by lncRNA:CR43306 deficiency through ferroptosis in Drosophila. (animal study)
- Ito et al., 2023. Age-related advanced glycation end-product accumulation impairs mitochondrial regulation after vitrification†. (animal study)
Words on this page
- SMD (standardized mean difference)
- A way to compare results measured on different scales. About 0.2 is a small effect, 0.5 medium, and 0.8 large.
- 95% CI (confidence interval)
- The range where the true result likely lies. If the range includes no effect (1 for ratios, 0 for differences), the result is not clear.
- p-value (p =)
- How likely a result this large would be by chance if there were no real effect. Below 0.05 is usually called a clear result.
- Placebo
- A dummy pill or fake treatment, so people do not know which group they are in.
- Pooled review (meta-analysis)
- A study that combines the results of many earlier studies to get one overall answer.
- mmHg
- The unit for blood pressure.
- Marker
- A lab or scan result that stands in for a health outcome. A better marker does not always mean better health.
How the short answer is set
Fixed rules turn the studies into the short answer, so the same studies always give the same answer. The rules start from GRADE, a standard system for rating evidence, in plain language.
| Confidence | What it means |
|---|---|
| High | We are confident the answer is right. |
| Moderate | The answer is probably right, but it could change. |
| Low | The answer may well change. |
| Very low (this page) | Any answer is very uncertain. |
| Not tested in people | Only cell or animal studies exist. |
Why very low here
- Most trials were small, short, or pilot studies in specific groups.
- Memory results disagree: one 24-month trial found a gain, a pooled review found none.
- Many trials measured only blood, vessel or bone markers, not aging itself.
- No human study measured lifespan; longer-life results come from yeast, worms and mice.
Hard limit used. No study in people measured lifespan, frailty or new age-related disease, so the evidence cannot show that resveratrol slows aging itself in people.
How this page was made
Label
- Search
- PubMed, Nov 14, 2026. Searches written by Claude Opus 5.5; papers ranked by PubMed
- First read of all 48 papers
- Claude Sonnet
- Independent second read
- Claude Haiku
- Disagreements settled by
- Claude Opus 5.5
- Page text written by
- Claude Opus 5.5
- Charts
- Drawn by code from the study records
- Source check by a person
- Not yet. Required before search engines may list this page.
- Expert review
- No
- Papers read in full
- 0 of 48; all from PubMed abstracts
- Method
- v0.2, created Nov 14, 2026
Search. We ran four PubMed searches for resveratrol and aging and age-related disease: pooled and systematic reviews since 2012 (10 of 40), trials in people (22 of 41), population studies (10 of 27), animal studies (6 of 563). The first number is how many papers we read; the second is how many PubMed found. We took the ones PubMed ranks as most relevant. See the full PubMed search. Of the 48 papers read, 22 were on topic.
Limits. Digestery reads at most about 60 papers per question, so large fields are sampled, not covered in full. Abstracts can leave out key details, such as side effects and funding.
Review queue
These items wait for a person. Search engines are asked not to list the page until the first one is done.
- OpenThe short answer is new. It waits for a source check by a person.
- OpenWong 2020 and Thaung Zaw 2021 report the same RESHAW trial; count it once when tallying trials and people.
- OpenRESHAW papers list 104 weeks; each woman took resveratrol for 52 weeks of a 24-month crossover. Check before the dose picture.
- OpenJaskulski 2020 (breast cancer survivors; higher blood resveratrol linked to poorer prognosis) kept off-topic as cancer prognosis. Please confirm.
- OpenHecker 2022 (skin photo-aging review) and Huang 2024 (fly testicular aging) kept off-topic as organ-specific aging. Please confirm.
- OpenSánchez-Nieto 2023 prints the delayed-memory 95% CI as 0.85-2.23, which excludes its estimate 0.69; a minus sign is likely missing.
- OpenBaur 2006 competing interests are only on the Nature website; the company is not named in PubMed.
- OpenSix trial papers have no conflict statement in PubMed: Wong 2020, Diaz 2020, Wong 2016, Gliemann 2013, Pollack 2017, Huhn 2018.
- OpenHarper 2021 gives only within-group changes; no between-group test in the abstract, so the walking gains are uncertain.
- OpenSemba 2014 is tagged Randomized Controlled Trial in PubMed but is an observational study of urine levels.
Page history
| Date | Change | Reason |
|---|---|---|
| Nov 14, 2026 | Page created from 48 papers. | First version of the page. |
Flag an error
A flag must point to a source: the passage in the paper, or a link to a study this page missed. A flag starts a new check. Votes never change a page.